World's Best Scientists 2026 revealed!
Award Badge
Medicine
Korea
2026

D-Index & Metrics

Medicine

D-Index
129
Citations
93123
World Ranking
2527
National Ranking
1

Research.com Recognitions

  • 2026 - Research.com Medicine in Korea Leader Award
  • 2025 - Research.com Medicine in Korea Leader Award
  • 2023 - Research.com Medicine in Korea Leader Award
  • 2022 - Research.com Medicine in Korea Leader Award

Overview

Yung-Jue Bang is affiliated with Seoul National University in South Korea and has published extensively in the field of medicine, with a particular focus on oncology. Their primary research interests include gastric cancer management, colorectal cancer treatments, cancer immunotherapy, and gastrointestinal tumor research.

Their publication record includes frequent contributions to several key journals in oncology and related fields. Notable publication venues include:

  • Journal of Clinical Oncology (35 publications)
  • Clinical Cancer Research (9 publications)
  • Annals of Oncology (5 publications)
  • The Lancet Oncology (4 publications)
  • Cancer Research and Treatment (4 publications)

Their research encompasses a range of subfields within medicine, highlighting oncology (97 publications), pulmonary and respiratory medicine (70 publications), surgery (23 publications), gastroenterology (16 publications), and cancer research (12 publications).

Main topics explored in their work cover various aspects of cancer research and treatment:

  • Gastric Cancer Management and Outcomes (104 publications)
  • Colorectal Cancer Treatments and Studies (46 publications)
  • Cancer Immunotherapy and Biomarkers (42 publications)
  • HER2/EGFR in Cancer Research (38 publications)
  • Gastrointestinal Tumor Research and Treatment (32 publications)
  • Pancreatic and Hepatic Oncology Research (28 publications)
  • Esophageal Cancer Research and Treatment (24 publications)

Frequent collaborators include:

  • Kohei Shitara (42 joint publications)
  • Hyun Cheol Chung (29 joint publications)
  • Eric Van Cutsem (29 joint publications)
  • Min-Hee Ryu (17 joint publications)
  • Charles S. Fuchs (16 joint publications)

Recent notable papers authored or co-authored by Yung-Jue Bang include:

  • "Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study," published in 2020 in The Lancet Oncology
  • "KRAS G12C Inhibition with Sotorasib in Advanced Solid Tumors," published in 2020 in New England Journal of Medicine
  • "Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer," published in 2020 in New England Journal of Medicine
  • "Efficacy and Safety of Pembrolizumab or Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone for Patients With First-line, Advanced Gastric Cancer," published in 2020 in JAMA Oncology
  • "Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial," published in 2023 in The Lancet

Best Publications

  • Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial

    Yung Jue Bang;Eric Van Cutsem;Andrea Feyereislova;Hyun C. Chung

  • Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer

    Eunice L. Kwak;Yung-Jue Bang;D. Ross Camidge;Alice T. Shaw

  • Sunitinib malate for the treatment of pancreatic neuroendocrine tumors.

    Eric Raymond;Laetitia Dahan;Jean Luc Raoul;Yung Jue Bang

  • Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 Study.

    Aurelien Marabelle;Dung T. Le;Paolo A. Ascierto;Anna Maria Di Giacomo

  • Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study.

    Aurélien Marabelle;Marwan Fakih;Juanita Lopez;Manisha Shah

  • Crizotinib in ROS1-Rearranged Non–Small-Cell Lung Cancer

    Alice T. Shaw;Sai Hong I. Ou;Yung Jue Bang;D. Ross Camidge

  • Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial

    Yung Jue Bang;Young Woo Kim;Han Kwang Yang;Hyun Cheol Chung

  • Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer: Phase 2 Clinical KEYNOTE-059 Trial

    Charles S. Fuchs;Toshihiko Doi;Raymond W. Jang;Raymond W. Jang;Kei Muro

  • Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study.

    D. Ross Camidge;Yung Jue Bang;Eunice L. Kwak;A. John Iafrate

  • KRASG12C Inhibition with Sotorasib in Advanced Solid Tumors.

    David S. Hong;Marwan G. Fakih;John H. Strickler;Jayesh Desai

  • Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial

    Kohei Shitara;Mustafa Özgüroğlu;Yung-Jue Bang;Maria Di Bartolomeo

  • Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis.

    Alice T. Shaw;Beow Y. Yeap;Benjamin J. Solomon;Gregory J. Riely

  • Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial

    Kei Muro;Hyun Cheol Chung;Veena Shankaran;Ravit Geva

  • Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): 5-year follow-up of an open-label, randomised phase 3 trial.

    Sung Hoon Noh;Sook Ryun Park;Han Kwang Yang;Hyun Cheol Chung

  • Predictive and Prognostic Impact of Epidermal Growth Factor Receptor Mutation in Non–Small-Cell Lung Cancer Patients Treated With Gefitinib

    Sae-Won Han;Tae-You Kim;Pil Gyu Hwang;Soohyun Jeong

  • Phase I and pharmacokinetic study of Genexol-PM, a cremophor-free, polymeric micelle-formulated paclitaxel, in patients with advanced malignancies.

    Tae You Kim;Dong-Wan Kim;Jae-Yong Chung;Sang Goo Shin

  • Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer

    Kohei Shitara;Yung-Jue Bang;Satoru Iwasa;Naotoshi Sugimoto

  • T-Cell–Inflamed Gene-Expression Profile, Programmed Death Ligand 1 Expression, and Tumor Mutational Burden Predict Efficacy in Patients Treated With Pembrolizumab Across 20 Cancers: KEYNOTE-028

    Patrick A. Ott;Yung Jue Bang;Sarina A. Piha-Paul;Albiruni R. Abdul Razak

  • Efficacy and Safety of Pembrolizumab or Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone for Patients With First-line, Advanced Gastric Cancer: The KEYNOTE-062 Phase 3 Randomized Clinical Trial.

    Kohei Shitara;Eric Van Cutsem;Yung Jue Bang;Charles Fuchs

  • HER2-targeted therapies — a role beyond breast cancer

    Do Youn Oh;Yung Jue Bang

Frequent Co-Authors

Seock-Ah Im
Seock-Ah Im Seoul National University Hospital
Dae Seog Heo
Dae Seog Heo Seoul National University Hospital
Dong-Wan Kim
Dong-Wan Kim Seoul National University Hospital
Se-Hoon Lee
Se-Hoon Lee Sungkyunkwan University
Hyun Cheol Chung
Hyun Cheol Chung Yonsei University
Woo Ho Kim
Woo Ho Kim Seoul National University
Yoon-Koo Kang
Yoon-Koo Kang Asan Medical Center
Kohei Shitara
Kohei Shitara Yahoo (United Kingdom)

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring alternative pathways in healthcare is increasingly popular for those interested in medicine. Many students are seeking flexible and affordable online options to advance their education and careers in nursing and allied health fields.

For registered nurses aiming to earn a bachelor's degree, the cheapest rn to bsn programs offer a budget-friendly and convenient solution. Those looking to progress further in their careers may consider pursuing doctoral education; the cheapest phd nursing programs give aspiring nurse leaders an accessible path to achieving their goals.

Individuals with a non-nursing bachelor's degree can also pivot into the field through the non nursing bachelor's to msn online pathway, streamlining their transition into advanced nursing roles. If you're just getting started, consider online adn programs that offer entry-level access to a nursing career with less competitive admissions criteria.

These flexible options allow more students to gain qualifications that open doors in the health sector, making it easier and more affordable to pursue medical and healthcare careers.

Best Scientists Citing Yung-Jue Bang

Trending Scientists

Recently Published Articles